Project Details


The object of this study is to determine the safety of percutaneously delivered, intralesionally injected adeno-virus p53 construct (adeno-p53) in patients with hepatocellular carcinomas (HCC) and to investigate the potential anti-tumor effects of intralesional adeno-p53 given by monthly percutaneous injections. HCC is one of the three most common tumors to afflict humans. There is a great need for non-cytotoxic drugs for HCC in view of the underlying cirrhosis & the limitation of the diseased liver to withstand the hepatotoxic actions of almost all of the currently available cancer chemotherapeutic agents.
Effective start/end date10/1/999/30/02


  • National Center for Research Resources


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.